New hope for liver cancer: immune-boosting drug targets hepatitis b patients
NCT ID NCT03419481
First seen Mar 08, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This study tests a drug called pembrolizumab in 30 people with liver cancer caused by hepatitis B. The drug helps the immune system fight cancer. Researchers will check if tumors shrink and how the immune system changes during treatment. Participants must have stable hepatitis B and be well enough for tumor biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.